Abrocitinib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CHUIKYO (Japan), DMC (Denmark) and G-BA (Germany), among others, recommended or restricted abrocitinib, while AOTMIT (Poland) and CONITEC (Brazil) did not recommend it.
The record spans 3.9 years, opening at PBAC (Australia) in 2021 and running to 26 Jun 2025.
CIPM (Spain) changed its position: not recommended on 29 Sep 2022, recommended by 17 Jul 2024, after a resubmission.
No assessment is on file from PHARMAC (New Zealand), which is among the eight highest-volume agencies here.
The file is active: 12 of 21 records date from 2023 or later.
3 distinct indication wordings are recorded for abrocitinib by the agencies that label one in English (AWMSG, PBAC and SMC).
2 of these 21 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
PBAC (Australia) was first to assess abrocitinib, in 2021; AOTMIT (Poland) did not open a file until 26 Jun 2025 — a wide spread of 3.9 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 5 years in total.
7 of the 13 agencies here assessed abrocitinib more than once, HAS (France) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
abrocitinib has been through 13 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for abrocitinib reads 10 recommended, 5 not recommended, 3 restricted and 1 no benefit, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AOTMIT (Poland) | 26 Jun 2025 | programu lekowego B.124 „Leczenie chorych z atopowym zapaleniem skóry (ICD-10: L20) | not recommended | source |
| CONITEC (Brazil) | 29 Oct 2024 | Tratamento de dermatite atópica moderada a grave em adultos. | not incorporated | source |
| G-BA (Germany) | 17 Oct 2024 | Cibinqo — benefit assessment §35a | added benefit: not proven | source |
| HAS (France) | 17 Jul 2024 | Indication extension | SMR substantial · ASMR V | source |
| CIPM (Spain) | 17 Jul 2024 | Indicación terapéutica autorizada: Cibinqo está indicado para el tratamiento de la dermatitis atópica de moderada a grav… | financed by the SNS · art. 92 a, c | source |
16 further decisions for abrocitinib, across 12 agencies, are not shown here. They link to 12 further source documents.
Related molecules
- dupilumab — same ATC class D11A — Other dermatologicals
- nemolizumab — same ATC class D11A — Other dermatologicals
- lebrikizumab — same ATC class D11A — Other dermatologicals
- delgocitinib — same ATC class D11A — Other dermatologicals
- diclofenac — same ATC class D11A — Other dermatologicals
- ivermectin — same ATC class D11A — Other dermatologicals
Coverage: 21 decisions for abrocitinib from 13 agencies, 2021 to 2025. Data to 7 Sep 2026. ATC class D11A — Other dermatologicals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.